Relationship between plasma IP-10/CXCL10 levels and the initial therapeutic response in patients treated with Atezolizumab plus Bevacizumab for unresectable hepatocellular carcinoma.

Hitomi Takada,Koji Yamashita,Leona Osawa,Yasuyuki Komiyama,Natsuko Nakakuki,Masaru Muraoka,Yuichiro Suzuki,Mitsuaki Sato,Shoji Kobayashi,Takashi Yoshida,Shinichi Takano,Shinya Maekawa,Nobuyuki Enomoto

Oncology（2023）

引用 0|浏览10

暂无评分

摘要

High baseline IP-10/CXCL10 levels may be associated with better outcome, and high IP-10/CXCL10 ratio after 3-12 weeks may be associated with worse outcome in u-HCC patients receiving AB therapy.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要